PEITC for Health & Longevity

Evidence Review created on 04/26/2026 using AI4L / Opus 4.7

Also known as: Phenethyl Isothiocyanate, 2-Phenethyl Isothiocyanate, β-Phenethyl Isothiocyanate, 2-Isothiocyanatoethylbenzene

Motivation

PEITC (phenethyl isothiocyanate) is a naturally occurring sulfur-containing compound released when watercress and certain other cruciferous vegetables are chewed, chopped, or crushed. Among the dietary isothiocyanates, PEITC has reached the most advanced stage of human clinical investigation, with multiple randomized trials evaluating its activity against tobacco-related lung carcinogens and against progression of head-and-neck cancer.

Watercress (Nasturtium officinale) is the richest dietary source, while smaller amounts appear in turnips, radishes, garden cress, and other plants of the Brassicales family. Modest dietary intakes have been linked in observational research with reductions in DNA damage and improved detoxification of environmental toxicants — particularly in individuals whose genetics cause isothiocyanates to clear from the body more slowly.

This review examines the available evidence for PEITC — its mechanisms, the human and preclinical data supporting potential benefits, the safety considerations that emerge at concentrated doses, and the practical approaches to obtaining it through diet and limited supplemental forms in the longevity context.

Benefits - Risks - Protocol - Conclusion

Grokipedia

No dedicated Grokipedia article exists for PEITC.

Isothiocyanate

The Isothiocyanate page covers the broader isothiocyanate class and explicitly identifies PEITC ((2-isothiocyanatoethyl)benzene, C₆H₅CH₂CH₂–N=C=S) as a prominent natural derivative, but does not host a dedicated entry for phenethyl isothiocyanate.

Examine

No Examine.com article exists for PEITC. Examine covers the structurally related sulforaphane extensively but has not published a dedicated page for phenethyl isothiocyanate or watercress.

ConsumerLab

No ConsumerLab article exists for PEITC. While watercress extracts and cruciferous vegetable extracts containing PEITC are commercially available, ConsumerLab has not published a review focused on PEITC or watercress supplementation.

Systematic Reviews

A summary of systematic reviews and meta-analyses evaluating PEITC from PubMed.

Protective Effect of Isothiocyanates from Cruciferous Vegetables on Breast Cancer: Epidemiological and Preclinical Perspectives - Ngo et al., 2021

Systematic review covering 16 human studies, 4 animal studies, and 65 in vitro studies examining the protective effect of cruciferous vegetables and their isothiocyanate constituents (including PEITC, BITC (benzyl isothiocyanate, an isothiocyanate found primarily in garden cress and papaya seeds), and sulforaphane) on breast cancer. PEITC and other isothiocyanates reduced cancer cell viability through cell cycle arrest, apoptosis, and modulation of phase II detoxification enzymes, though human epidemiological evidence on cruciferous vegetable intake and breast cancer outcomes remained controversial across study populations.

Mechanism of Action

PEITC exerts its biological effects through several interconnected pathways:

Phase I/II enzyme modulation: PEITC inhibits cytochrome P450 enzymes (particularly CYP2A6 and CYP2A13, the liver and lung enzymes that activate the tobacco carcinogen NNK (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco-specific nitrosamine) into DNA-damaging forms), while inducing phase II detoxification enzymes — glutathione S-transferases, UGTs (UDP-glucuronosyltransferases, enzymes that conjugate compounds with glucuronic acid for excretion), and NAD(P)H quinone oxidoreductase 1 — through Nrf2 (nuclear factor erythroid 2-related factor 2, a transcription factor that activates cellular antioxidant defense genes) activation. This dual action shifts metabolic balance toward elimination of carcinogens and toxicants.
Apoptosis induction via ROS generation: PEITC triggers mitochondria-mediated apoptosis (programmed cell death) by elevating intracellular ROS, depolarizing the mitochondrial membrane, releasing cytochrome c, and activating caspase-9 and caspase-3 (enzymes that execute the cell death cascade). It upregulates pro-apoptotic Bax and downregulates anti-apoptotic Bcl-2 (B-cell lymphoma 2, a protein that prevents programmed cell death).
Cell cycle arrest: PEITC induces G2/M phase arrest through downregulation of cyclin B1 and CDK1 (cyclin-dependent kinase 1, an enzyme essential for initiating cell division), and activates the DNA damage response via ATM (ataxia telangiectasia mutated, a kinase that detects DNA damage), Chk2 (checkpoint kinase 2, an enzyme that halts cell division when DNA damage is detected), and p53 signaling.
Androgen receptor suppression: In prostate cancer cells, PEITC downregulates androgen receptor (AR) expression and disrupts AR-mediated signaling, providing a mechanism distinct from most other isothiocyanates and relevant to androgen-dependent cancer prevention.
Epigenetic modulation: PEITC acts as an HDAC (histone deacetylase, enzymes that remove acetyl groups from histones, generally silencing gene expression) inhibitor and influences DNA methylation patterns, potentially reactivating tumor suppressor genes. Recent work shows PEITC can reactivate mutant p53 protein function — a mechanism implicated in the Nutri-PEITC oral cancer trial.
Metastasis & angiogenesis suppression: PEITC inhibits matrix metalloproteinases MMP-2 and MMP-9 (enzymes that break down structural barriers between tissues, enabling cancer cell invasion), suppresses HIF-1α (hypoxia-inducible factor 1-alpha, a protein that activates genes promoting blood vessel growth in low-oxygen conditions)/VEGF (vascular endothelial growth factor, a signaling protein that stimulates blood vessel formation) signaling, and modulates Wnt/β-catenin (a developmental signaling pathway that regulates cell proliferation and is frequently overactive in cancer) and STAT-3 (signal transducer and activator of transcription 3, a protein relaying growth and inflammation signals) pathways.
GST inhibition with cancer-cell selectivity: PEITC irreversibly inhibits glutathione S-transferases via covalent modification, depleting glutathione (GSH) selectively in cancer cells with already elevated baseline ROS, sensitizing them to apoptosis while sparing normal cells with adequate antioxidant reserves.

Key pharmacological properties: PEITC has poor aqueous solubility but reasonable oral bioavailability through its lipophilic character. After ingestion of 100 g of watercress (~25 mg PEITC), peak plasma concentration of approximately 1.0 μM is reached at 2.6 hours, with a plasma half-life of approximately 5 hours. Tissue distribution is broad due to lipophilicity, with preferential accumulation in lung, liver, kidney, intestinal epithelium, and bladder — tissues that also bear the highest first-pass exposure to ingested isothiocyanates and to inhaled or systemically circulating carcinogens. PEITC binds reversibly to serum albumin in plasma, which moderates free-concentration peaks. PEITC is rapidly conjugated with glutathione by glutathione S-transferases and excreted in urine via the mercapturic acid pathway as N-acetyl-S-(N-phenethylthiocarbamoyl)-L-cysteine.

Historical Context & Evolution

Phenethyl isothiocyanate has been recognized as a constituent of watercress and related Brassicales species since glucosinolate-isothiocyanate biochemistry was characterized in the mid-20th century. Watercress itself has a long history in European herbal traditions, used for scurvy, respiratory complaints, and as a tonic — Hippocrates is said to have grown it near a spring at Kos for his patients.

Modern interest in PEITC’s chemopreventive properties began in the 1980s through the work of Stephen Hecht and colleagues at the American Health Foundation and later the University of Minnesota, who demonstrated that PEITC effectively blocks lung carcinogenesis induced by the tobacco-specific nitrosamine NNK in rodent models. This led to the National Cancer Institute formally adopting PEITC into its chemoprevention drug development pipeline in 1996, making it the first isothiocyanate to advance through structured clinical development.

A series of human pharmacokinetic and chemoprevention trials followed: a phase I dose-finding study at NYU established tolerability up to 120 mg/day, with 40 mg/day emerging as the well-tolerated standard. The 2016 randomized crossover trial by Yuan et al. (PMID 26951845) demonstrated that 40 mg PEITC daily reduced metabolic activation of NNK by 7.7% in 82 cigarette smokers, with markedly stronger effects in smokers carrying null genotypes for GSTM1 and GSTT1 (glutathione S-transferase M1 and T1, two enzymes that conjugate and clear isothiocyanates from the body) — providing the first human evidence that PEITC modifies tobacco carcinogen metabolism.

Subsequent investigation has shifted toward functional food formulations, exemplified by the Nutri-PEITC jelly developed in Thailand for advanced oral cancer patients (Lam-Ubol et al., 2023, PMID 37175527), which delivered 20 mg PEITC daily in a soft texture-modified diet and showed improved progression-free survival and quality of life in a 72-patient randomized trial. Watercress-based functional beverages have also entered clinical trials at the University of Minnesota for environmental toxicant detoxification.

Despite this progress, PEITC remains an investigational compound. No regulatory approval exists for PEITC as a drug, and supplementation has not crossed into mainstream evidence-based practice — partly because of the documented genotoxicity at high concentrations and concerns about cumulative toxicity raised by the Linus Pauling Institute and other authoritative groups.

Expected Benefits

Medium 🟩 🟩

Tobacco Carcinogen Detoxification

PEITC inhibits the metabolic activation of NNK and other tobacco-specific carcinogens while inducing phase II conjugation of volatile organic toxicants. The 2016 Yuan et al. randomized crossover trial in 82 cigarette smokers (40 mg/day for 1 week) reduced the NNK metabolic activation ratio by 7.7% (P = 0.023) and increased mercapturic acid formation from benzene by 24.6% (P = 0.002) and acrolein by 15.1% (P = 0.005). The protective effect was substantially larger in GSTM1/GSTT1-null smokers, with benzene detoxification rising 95.4% — aligning with epidemiology showing isothiocyanates protect against lung cancer most strongly in this genetic subgroup.

Magnitude: 7.7% reduction in NNK metabolic activation overall; 95.4% increase in benzene detoxification in GSTM1/GSTT1-null smokers (40 mg/day, 1 week).

Improved Outcomes in Advanced Oral Cancer (Adjunctive)

A 72-patient blinded randomized placebo-controlled trial (Lam-Ubol et al., 2023, PMID 37175527) tested 20 mg PEITC delivered daily in a 200 g nutritious jelly matrix, 5 days per week for 12 weeks, in patients with advanced oral or oropharyngeal cancer. The PEITC arm showed significantly longer progression-free survival, higher proportions of stable disease and improved health-related quality of life, and increased serum p53 levels (P < 0.001 for HRQOL, stable disease, and p53; P < 0.05 for progression-free survival), with no serious intervention-related adverse events.

Magnitude: Significantly longer progression-free survival vs. placebo (P < 0.05); higher rates of stable disease and quality-of-life improvement (P < 0.001) at 20 mg PEITC daily for 12 weeks.

Low 🟩

Anticancer Activity (Preclinical Cancer Chemoprevention)

PEITC demonstrates apoptosis induction, cell cycle arrest, and metastasis inhibition across breast, prostate, lung, colon, pancreatic, leukemia, and head-and-neck cancer cell lines and animal models. In prostate cancer, PEITC suppresses androgen receptor signaling — a mechanism distinct from sulforaphane and BITC. Preclinical efficacy has been demonstrated through multiple mechanisms detailed in the Gupta et al. (2014) comprehensive review (PMID 25152445) and the Ngo et al. (2021) breast cancer systematic review.

Magnitude: IC50 (half-maximal inhibitory concentration, the drug concentration needed to inhibit cell growth by 50%) values in the low-to-mid micromolar range across multiple cancer cell lines; ~50% tumor xenograft growth inhibition in mouse models. Human chemoprevention efficacy has only been demonstrated for biomarker outcomes, not cancer incidence.

Reduced Oxidative DNA Damage

PEITC’s induction of phase II detoxification enzymes and direct conjugation of electrophilic carcinogens reduces oxidative damage to nuclear DNA, the basis of one of the most-studied biomarkers of cancer risk. The Watercress in Detoxification of Environmental Toxicants and Carcinogens trials (NCT03978117, completed 2024) and earlier human watercress feeding studies have shown that 8 weeks of daily watercress consumption reduces lymphocyte DNA damage as measured by comet assay and improves antioxidant status, with stronger effects in smokers and individuals with low baseline carotenoid levels. Effects observed in mixed dietary watercress trials cannot be cleanly attributed to PEITC alone given watercress’s broader nutrient and phytochemical content.

Magnitude: Approximately 17% reduction in lymphocyte DNA damage and approximately 100% increase in plasma carotenoids over 8 weeks of daily watercress (85 g/day) in earlier human trials.

Anti-Inflammatory Effects

PEITC suppresses NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells, a protein complex controlling inflammation and immune responses) signaling and downregulates inflammatory mediators such as TNF-α (tumor necrosis factor alpha, a major pro-inflammatory cytokine), IL-6 (interleukin-6, a pro-inflammatory cytokine), and COX-2 (cyclooxygenase-2, an enzyme producing inflammatory prostaglandins) in cell culture and animal models. The 2016 Yuan trial measured urinary 8-iso-prostaglandin F2α and prostaglandin E2 metabolites in smokers and found no change at 40 mg/day for 1 week, suggesting human anti-inflammatory effects may require larger doses or longer exposure than carcinogen detoxification.

Magnitude: Not quantified in available studies.

Speculative 🟨

Anti-Obesity & Metabolic Effects

A 2025 ScienceDirect mechanistic study reported that PEITC ameliorates high-fat-diet-induced obesity in mice by antagonizing hypothalamic leptin resistance. No human metabolic studies have been conducted.

Antimicrobial & Antiparasitic Activity

PEITC and other isothiocyanates from watercress show in vitro activity against Helicobacter pylori, Listeria, and certain pathogenic fungi, including agents implicated in foodborne infections. Human clinical evidence is limited.

Cardiovascular Protection

Watercress consumption has been linked in observational studies and small intervention trials to lower triglycerides, reduced lipid peroxidation, and improved endothelial function. Whether PEITC specifically (versus the broader nutrient and phytochemical content of watercress) drives these effects is unclear.

Neuroprotection

PEITC’s Nrf2-activating and anti-inflammatory properties suggest theoretical neuroprotective potential paralleling sulforaphane research. No clinical neurology data exist for PEITC.

Benefit-Modifying Factors

The following considerations are largely inferred from the broader isothiocyanate literature, though some have direct PEITC human evidence:

GSTM1/GSTT1 genotype: Null genotypes result in slower PEITC clearance and prolonged tissue exposure. The 2016 Yuan trial demonstrated dramatically larger detoxification effects in GSTM1/GSTT1 double-null smokers (95.4% increase in benzene mercapturic acid vs. essentially no effect in those carrying both genes), making this the most well-characterized pharmacogenetic factor for PEITC.
Smoking and other oxidative-stress states: Individuals with elevated baseline oxidative stress, ongoing carcinogen exposure (smokers, those with occupational exposures), or low antioxidant status may experience the most pronounced relative benefit from PEITC’s Nrf2 activation and phase II induction.
Sex-based differences: No clear sex-specific differences in PEITC efficacy have been established; the major chemoprevention trials enrolled both men and women without significant interaction effects.
Age: Nrf2 activity and phase II enzyme expression decline with age. Older individuals may derive greater relative benefit from Nrf2 activators, though no PEITC-specific age data exist.
Pre-existing conditions: Individuals with chronic inflammatory states, head-and-neck cancer (the population of the Nutri-PEITC trial), or genetically elevated cancer risk may benefit most. The Nutri-PEITC oral cancer trial is the only human evidence of disease-state benefit.
Baseline biomarker status: Lower baseline carotenoids, glutathione, and antioxidant capacity correlate with larger DNA damage reductions in watercress feeding studies, suggesting baseline antioxidant deficiency may amplify benefit.

Potential Risks & Side Effects

Medium 🟥 🟥

Gastrointestinal Side Effects

Mild gastrointestinal effects are the most common adverse events reported in PEITC clinical trials. The 2016 Yuan et al. trial (40 mg/day, 1 week) reported dry mouth, taste alteration, stomach ache, belching, flatulence, and diarrhea — none in the severe grade. The earlier phase I study at NYU showed dose-dependent GI distress, with 120 mg/day producing more diarrhea and abdominal discomfort than 40 mg/day. Watercress itself is generally well-tolerated dietarily but can cause mild GI irritation in sensitive individuals.

Magnitude: Mild-to-moderate GI symptoms reported in approximately 20-40% of subjects at 40 mg/day; more frequent and pronounced at 120 mg/day.

Low 🟥

Genotoxicity at High Concentrations

Like other isothiocyanates, PEITC is documented as a genotoxin at supraphysiological concentrations in mammalian cell cultures, inducing chromosome aberrations, sister chromatid exchanges, and DNA strand breaks. The Linus Pauling Institute explicitly cautions that concentrated isothiocyanate sources, including PEITC supplements and freeze-dried cruciferous powders, can damage DNA in normal cells with cumulative effects of regular intake. In vivo, these effects are partially attenuated by serum albumin, glutathione, and gastric protein binding.

Magnitude: Genotoxic effects observed in vitro at concentrations overlapping with anticancer doses (5-50 μM); attenuated under in vivo conditions.

Thyroid Disruption (Theoretical)

Cruciferous-vegetable-derived compounds including PEITC have a theoretical thyroid-disrupting potential through goitrogenic effects in iodine-deficient individuals. Clinical data with concentrated isothiocyanates have not consistently shown adverse thyroid effects in iodine-sufficient subjects, but high intakes of raw watercress in iodine-deficient populations have historically been associated with goiter risk.

Magnitude: Not quantified in available studies.

Speculative 🟨

Renal & Bladder Effects

Animal toxicity studies of related isothiocyanates (BITC subacute toxicity studies) have shown dose-dependent renal dysfunction and bladder epithelial changes at high oral doses. PEITC and its mercapturic acid metabolites are renally excreted, and the same theoretical concerns apply, though no PEITC-specific human renal or bladder toxicity has been documented at clinical doses.

Drug Interactions via Phase I Inhibition

PEITC’s inhibition of CYP enzymes raises theoretical concerns about altered metabolism of co-administered drugs. No clinically significant drug interactions have been reported in human PEITC trials, but most participants were not on chronic medications metabolized by the affected pathways.

Embryotoxicity

Some isothiocyanates show embryotoxic effects in animal models at high doses. No embryotoxicity data exist for PEITC specifically; pregnancy and breastfeeding caution is prudent given the class effect.

Cumulative Tissue Burden with Chronic Supplementation

Concerns have been raised that regular intake of PEITC supplements could cause buildup with cumulative cellular effects. Long-term human safety data beyond 12 weeks of clinical exposure do not exist.

Risk-Modifying Factors

GSTM1/GSTT1 genotype: Null genotypes that amplify benefit also slow clearance of PEITC, potentially increasing exposure duration and theoretically increasing the risk of adverse effects at higher doses.
Baseline biomarker levels: Low baseline glutathione status, low total antioxidant capacity, or chronically depleted reduced-thiol pools (e.g., from chronic acetaminophen use, alcohol use, or critical illness) reduce the buffering capacity for PEITC’s electrophilic chemistry, theoretically increasing the risk of off-target reactivity at concentrated supplemental doses. Conversely, very low baseline oxidative stress markers (e.g., normal GGT, normal 8-iso-prostaglandin F2α) suggest minimal need for additional Nrf2 activation and a less favorable risk/benefit ratio for concentrated exposure.
Baseline kidney function: Given that PEITC and its metabolites are renally excreted, individuals with reduced glomerular filtration may face higher exposure. No human renal toxicity at clinical doses has been documented.
Iodine status: Iodine-deficient individuals may face higher theoretical thyroid-disrupting risk from concentrated isothiocyanate intake.
Sex-based differences: No sex-specific risk data exist for PEITC.
Age: No age-specific risk data exist for PEITC. Older adults with reduced renal function and polypharmacy face theoretically elevated risk.
Pre-existing conditions: Individuals with chronic kidney disease, hypothyroidism, gastrointestinal disorders, pregnancy, or active cancer being treated with chemotherapy should exercise additional caution with concentrated PEITC exposure.

Key Interactions & Contraindications

Prescription drug interactions: PEITC inhibits cytochrome P450 enzymes (particularly CYP2A6 and CYP2A13, which metabolize nicotine and tobacco-specific nitrosamines, and to a lesser extent CYP1A2, CYP2B1, and others) and induces phase II enzymes. Drugs with narrow therapeutic windows metabolized by these enzymes — including warfarin, cyclosporine, several chemotherapy agents (e.g., cisplatin, paclitaxel), and theophylline — should be co-administered with caution. Severity: caution. Consequence: altered drug exposure, potential efficacy loss or toxicity.
Over-the-counter medication interactions: NSAIDs (nonsteroidal anti-inflammatory drugs, common pain relievers like ibuprofen and aspirin) may have additive anti-inflammatory effects. Acetaminophen metabolism may be altered by phase II enzyme modulation; theoretically, PEITC could shift more acetaminophen toward toxic metabolites under glutathione-depleted conditions. Severity: caution. Consequence: altered analgesic effect or hepatic stress at high acetaminophen doses.
Supplement interactions: Other Nrf2 activators (sulforaphane, curcumin, resveratrol, broccoli sprout extracts, BITC) may have additive effects, both beneficial and theoretically genotoxic. Glutathione-depleting compounds (acetaminophen, certain heavy metal chelators) could increase PEITC tissue exposure. NAC (N-acetylcysteine, a glutathione precursor) could blunt PEITC’s pro-apoptotic ROS-dependent effects in cancer cells. Severity: caution. Consequence: altered efficacy.
Additive effects with cruciferous-rich diets: Combining concentrated PEITC supplementation with high cruciferous vegetable intake (broccoli sprouts, kale, cabbage) increases cumulative isothiocyanate exposure. Severity: caution. Consequence: amplified GI symptoms; theoretical genotoxicity at very high cumulative doses.
Chemotherapy interactions: Preclinical studies show PEITC enhances cisplatin, gemcitabine, and 5-FU (5-fluorouracil, a chemotherapy agent commonly used for gastrointestinal and head-and-neck cancers) activity, and the Nutri-PEITC oral cancer trial successfully combined PEITC with standard care. However, PEITC’s CYP inhibition could also alter chemotherapy pharmacokinetics. Severity: caution. Mitigation: oncology supervision.
Anticoagulant interactions: Watercress contains vitamin K, which can antagonize warfarin therapy. Severity: monitor. Mitigation: maintain consistent intake; INR (international normalized ratio, the standard blood test for monitoring warfarin anticoagulation) monitoring.
Populations who should avoid: Pregnant or breastfeeding women should avoid concentrated PEITC supplementation and standardized watercress extracts (whole-food intake at culinary levels is generally considered acceptable). Severity: caution given class-effect embryotoxicity in animals. Individuals with severe kidney disease (eGFR < 30 mL/min/1.73m², estimated glomerular filtration rate, the standard measure of kidney function) should avoid concentrated supplementation. Cancer patients on active chemotherapy should not self-supplement without oncologist guidance. Children and adolescents have no established safety data for concentrated PEITC.

Risk Mitigation Strategies

Obtain PEITC primarily through whole-food sources: Consuming PEITC through watercress (the richest dietary source, ~25-30 mg PEITC per 100 g raw watercress), garden cress, turnips, radishes, and other cruciferous vegetables provides the compound in a whole-food matrix at physiological levels with established dietary safety, mitigating cumulative toxicity concerns. The Linus Pauling Institute explicitly recommends this approach over concentrated supplementation.
Limit concentrated supplementation duration: If using PEITC-containing supplements (most commonly as standardized watercress extracts in cruciferous blends), limit chronic continuous use to 8-12 weeks at a time, mirroring the longest clinical trial durations, to mitigate theoretical cumulative DNA damage and renal exposure.
Avoid exceeding clinically tested doses: Stay at or below 40 mg/day PEITC if supplementing, since this is the dose tolerated in clinical trials with minimal adverse events. Do not exceed 120 mg/day under any circumstances, as this caused increased GI distress in dose-finding studies and approaches concentrations associated with in vitro genotoxicity. This mitigates both gastrointestinal side effects and theoretical genotoxicity.
Maximize myrosinase activation through food preparation: Raw consumption or light steaming (1-3 minutes) preserves myrosinase activity. Chopping watercress and allowing 5-10 minutes before further preparation maximizes PEITC formation. This mitigates the risk of consuming inactive glucosinolate without bioavailable PEITC.
Maintain adequate iodine intake: Ensure sufficient dietary iodine (≥150 μg/day for adults, with 250 μg/day during pregnancy and lactation) when consuming significant amounts of cruciferous vegetables or PEITC supplements, mitigating the theoretical thyroid-disrupting risk.
Take with food: Taking PEITC supplements with meals reduces gastrointestinal irritation, dry mouth, and taste alteration.
Periodic kidney and thyroid monitoring during chronic use: Annual creatinine, BUN (blood urea nitrogen, a marker of kidney filtration), and TSH (thyroid-stimulating hormone, the standard measure of thyroid function) testing during chronic use of concentrated cruciferous extracts mitigates the theoretical renal and thyroid risks.
Genetic screening for high-intake users: GSTM1/GSTT1 genotyping (available through commercial direct-to-consumer testing) can identify individuals likely to experience prolonged PEITC exposure from a given dose, who may benefit from lower supplemental doses or rely entirely on dietary sources to mitigate accumulation.

Therapeutic Protocol

No regulatory-approved therapeutic protocol exists for PEITC. The protocols below summarize approaches used in published clinical trials and dietary recommendations from authoritative reviewers:

Dietary protocol (preferred per Linus Pauling Institute and most expert reviews): Consume 30-100 g of watercress 3-7 times per week, prepared raw or lightly steamed (1-3 minutes maximum) to preserve myrosinase. 100 g of raw watercress provides approximately 25-30 mg of PEITC after chewing-induced glucosinolate hydrolysis. Other cruciferous sources include garden cress, turnips, radishes, and horseradish.
Functional food protocol (Nutri-PEITC, Lam-Ubol et al., 2023): 200 g of nutritious soft jelly fortified with 20 mg PEITC, consumed 5 days per week for 12 weeks. Used as an adjunct to standard cancer care in advanced oral cancer.
Chemoprevention research protocol (Yuan et al., 2016): 10 mg PEITC in 1 mL olive oil, taken orally 4 times per day with meals (40 mg/day total), for 1-week to 4-week courses in smokers.
Half-life and timing: Plasma half-life is approximately 5 hours, with peak plasma concentration approximately 2.6 hours after ingestion of 25 mg from watercress. Split dosing 3-4 times daily maintains more sustained tissue exposure than once-daily dosing for PEITC’s anticancer indications.
Single vs. split doses: Clinical trials of PEITC for chemoprevention have favored split dosing (10 mg × 4) to maintain steady plasma concentrations given the short half-life. For dietary intake, distributing watercress across multiple meals theoretically provides more continuous exposure than a single large serving.
Best time of day: No specific time-of-day data favor morning or evening dosing. Taking with meals reduces GI side effects.
Genetic considerations: GSTM1-null and GSTT1-null individuals experience prolonged PEITC exposure from a given dose; lower or less frequent dosing may be appropriate, and the largest detoxification benefits are seen in this group.
Sex-based differences: No sex-specific dosing protocols exist.
Age considerations: No formal age-specific protocols exist. Older adults with reduced renal function should consider lower doses; pediatric use has no safety data.
Baseline biomarkers: No established biomarker thresholds guide PEITC use. Glutathione status, urinary mercapturic acids, and DNA damage assays are research-grade and not routine clinical tools.
Pre-existing conditions: Smokers and individuals with high carcinogen exposure are the population in which efficacy has been demonstrated. Cancer patients and those with chronic disease should use only under medical supervision.
Standard practitioner protocol: No major integrative oncology or longevity protocol formally recommends PEITC supplementation. Life Extension and similar functional medicine outlets recommend watercress consumption and standardized cruciferous vegetable extracts (containing watercress alongside broccoli, cabbage, etc.) in preference to isolated PEITC. Where competing approaches exist, the dietary-first approach favored by the Linus Pauling Institute is presented alongside the functional food approach demonstrated in the Nutri-PEITC trial — neither has been directly compared.

Discontinuation & Cycling

Duration: As a dietary component, watercress and PEITC-containing cruciferous vegetables can be consumed indefinitely as part of a balanced diet. Concentrated PEITC supplementation has not been studied beyond approximately 12 weeks of continuous use; longer durations carry unknown cumulative risk.
Withdrawal effects: None known. Discontinuation removes ongoing Nrf2 activation, phase II enzyme induction, and any active chemopreventive effects.
Tapering: Not applicable for dietary intake or standard supplemental doses. No taper protocol is established.
Cycling: No formal cycling protocol exists. A reasonable practical approach for those using concentrated supplements is 8-12 week cycles separated by 4-week breaks, mirroring the longest tested clinical exposures and providing periods for any cumulative cellular effects to resolve. For dietary watercress, no cycling is needed.

Sourcing and Quality

Whole food sources (preferred): Fresh watercress is the richest dietary PEITC source (~25-30 mg per 100 g). Garden cress, turnip, radish, and horseradish provide additional but smaller amounts. Organic produce reduces pesticide exposure. Frozen watercress retains glucosinolate content but blanching may partially inactivate myrosinase, reducing PEITC yield — adding mustard seed powder restores conversion.
Standardized watercress extracts: Some cruciferous vegetable extract supplements list watercress and standardize for PEITC or total isothiocyanate content. Examples include Life Extension’s Triple Action Cruciferous Vegetable Extract and similar formulations from reputable companies. Look for explicit standardization (e.g., “X mg PEITC equivalents”) rather than total weight of watercress powder.
Isolated PEITC: Pharmaceutical-grade PEITC used in clinical trials is supplied in encapsulated olive oil for dose-controlled administration. Isolated PEITC is not widely available as a consumer supplement and is generally restricted to research applications (Sigma-Aldrich, Cayman Chemical, LKT Labs supply research-grade material that is not intended for human consumption).
Third-party testing: For watercress extract supplements, look for NSF, USP, or ConsumerLab certification to verify identity, potency, and absence of contaminants. Independent testing for actual PEITC content is rare for commercial products.
Quality flags: Avoid supplements claiming high PEITC doses without standardization, products from unverified suppliers, and supplements that combine PEITC with other concentrated isothiocyanate sources (compounding cumulative-exposure concerns). Be cautious of marketing claims that exceed published clinical evidence.

Practical Considerations

Time to effect: Phase II enzyme induction begins within hours of PEITC ingestion in cell-culture models. Mercapturic acid output from carcinogen detoxification rises within days of consistent dosing in clinical trials. Functional benefits (e.g., reduced lymphocyte DNA damage) require approximately 8 weeks of regular intake. The Nutri-PEITC oral cancer trial showed measurable progression-free-survival benefit at 12 weeks. Time to effect for theoretical longevity benefits is unknown.
Common pitfalls: Overcooking watercress (boiling, prolonged steaming) destroys myrosinase and dramatically reduces PEITC yield — a frequent mistake. Failing to chew thoroughly limits glucosinolate-myrosinase contact. Buying watercress that has been stored long after harvest reduces glucosinolate content. Choosing concentrated PEITC supplements without recognizing the Linus Pauling Institute and similar authoritative cautions about cumulative isothiocyanate exposure. Confusing PEITC with sulforaphane (different precursor, different food source, partially different mechanisms).
Regulatory status: PEITC is a naturally occurring food component. Watercress and cruciferous vegetable extracts containing PEITC are sold as dietary supplements under DSHEA (Dietary Supplement Health and Education Act, the U.S. federal law governing supplement regulation) rules. PEITC has investigational drug status in clinical trials but is not approved by the FDA or any equivalent regulator as a drug for any indication. Clinical use is off-label/investigational.
Cost and accessibility: Fresh watercress costs $3-6 per 100 g bunch in major U.S. markets; less expensive in regions where it grows commercially. Watercress-containing cruciferous vegetable extract supplements range from $15-30 for 60 capsules. Isolated PEITC is not commercially available for consumer use. Specialty Nutri-PEITC products from the Thai trial are not commercially available outside research settings.

Interaction with Foundational Habits

Sleep: No direct effects of PEITC on sleep have been studied. Watercress consumed at dinner is unlikely to disrupt sleep, though high-fiber meals close to bedtime may cause GI discomfort in sensitive individuals. Direction: none established. Mechanism: not characterized.
Nutrition: Watercress and other PEITC-rich cruciferous vegetables are nutrient-dense, providing fiber, vitamin C, vitamin K, folate, and minerals. The “hack and hold” preparation method (chopping, then waiting 5-10 minutes before any cooking) maximizes PEITC formation. Concurrent dietary fat intake improves PEITC absorption given its lipophilicity (the clinical trial protocol used olive oil as the vehicle). Direction: potentiating with fat co-administration. Mechanism: improved lipophilic compound absorption.
Exercise: No direct interaction between PEITC and exercise has been studied. Nrf2 activation may theoretically support exercise recovery by reducing oxidative stress, but excessive antioxidant supplementation could blunt exercise-induced hormetic adaptations — unlikely at dietary isothiocyanate levels but a theoretical concern at high supplemental doses. Direction: theoretical potentiation of recovery; theoretical blunting of adaptation only at high doses. Practical note: separate concentrated PEITC supplementation from intra-workout windows if concerned.
Stress management: Nrf2 activation by PEITC supports the cellular stress response by upregulating antioxidant and detoxification enzymes. No direct effects on cortisol or the HPA (hypothalamic-pituitary-adrenal, the hormonal axis controlling the body’s stress response) axis have been studied. Direction: indirect cellular stress resilience. Mechanism: Nrf2-mediated antioxidant upregulation.

Monitoring Protocol & Defining Success

PEITC is consumed primarily through dietary sources for chemoprevention and longevity goals, with no formal monitoring protocol established for either dietary intake or supplementation. For individuals using concentrated PEITC or watercress extract supplements, baseline and ongoing assessments should be considered as follows.

Baseline testing is recommended before starting concentrated PEITC supplementation to establish reference values for kidney, thyroid, and hepatic function. Ongoing monitoring during continuous supplementation is suggested every 6-12 months, or after each 8-12 week cycle if cycling is used.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
hs-CRP	< 1.0 mg/L	Tracks systemic inflammation	High-sensitivity C-reactive protein, a blood marker of systemic inflammation. Conventional range: < 3.0 mg/L. Fasting not required
Creatinine & eGFR	Cr 0.7-1.2 mg/dL (men), 0.5-1.0 mg/dL (women); eGFR > 90	Monitors kidney function	Relevant given renal excretion of PEITC metabolites. eGFR is the estimated glomerular filtration rate, the standard measure of kidney filtration. Conventional ranges similar
BUN	7-20 mg/dL	Complements creatinine for renal monitoring	Blood urea nitrogen. Conventional range: 6-24 mg/dL. Fasting preferred. Pair with creatinine
TSH	1.0-2.5 mIU/L	Monitors thyroid function with high cruciferous intake	Thyroid-stimulating hormone, the primary thyroid screening test. Conventional range: 0.4-4.0 mIU/L. Morning draw preferred
GGT	10-30 U/L	Proxy for oxidative stress and hepatobiliary status	Gamma-glutamyl transferase, sensitive to glutathione metabolism. Conventional range: 5-65 U/L. Fasting preferred
GSTM1/GSTT1 genotype	Determine null vs. positive status	One-time test to predict PEITC pharmacokinetics and response magnitude	Genetic testing via commercial direct-to-consumer or specialty labs. One-time test. Not part of routine clinical panels

Qualitative markers: Track GI tolerance (most useful day-to-day indicator), energy levels, taste perception, skin quality, and sense of general wellbeing. Note any new bruising, unusual fatigue, or thyroid symptoms (cold intolerance, hair changes, weight gain).

Emerging Research

Active clinical detoxification programs: The completed NCT03978117 trial at the Masonic Cancer Center, University of Minnesota (300 participants, completed 2024) tested freeze-dried watercress preparations against placebo for environmental toxicant detoxification, with focused analysis of GSTM1/GSTT1-null subjects. Final results are anticipated to clarify whether dietary-equivalent PEITC delivery confers measurable urinary mercapturic acid changes for benzene, acrolein, crotonaldehyde, and other carcinogens at scale.
Earlier landmark lung cancer chemoprevention trial: The completed NCT00691132 phase 2 trial at the University of Minnesota (107 enrolled smokers, completed) generated the foundational human chemoprevention data published as Yuan et al. 2016 (PMID 26951845) and Yuan et al. 2016 (PMID 27099270).
Nutri-PEITC for advanced oral cancer: The NCT03034603 trial in Thailand (96 enrolled, completed 2018) provided the basis for the Lam-Ubol et al. 2023 publication (PMID 37175527) showing improved progression-free survival and quality of life. Whether subsequent confirmatory trials will be undertaken in independent centers remains open.
Withdrawn lymphoproliferative disorder trial: NCT00968461, a phase 1 study of PEITC in fludarabine-treated lymphoproliferative disorder patients at MD Anderson, was withdrawn before enrollment, illustrating the uneven progress of PEITC clinical development.
PEITC and chemoresistance: Recent preclinical work (Ding et al., 2025, PMID 41171377) reports that PEITC restores chemosensitivity in cisplatin-resistant non-small cell lung cancer through c-Myc/miR-424-5p targeting, suggesting potential for combination chemotherapy applications; clinical translation has not yet occurred.
Metabolic syndrome and obesity: Mechanistic studies suggest PEITC ameliorates high-fat-diet-induced obesity in mice by antagonizing hypothalamic leptin resistance, opening a potential metabolic application that has not been tested in humans.
Drug delivery and bioavailability: Microencapsulated PEITC, liposomal formulations, and nanoemulsions are in active preclinical development to overcome PEITC’s poor aqueous solubility and rapid clearance, potentially enabling lower dose protocols with sustained tissue exposure. None have entered late-stage clinical testing.
Studies that could weaken the case: The modest 7.7% reduction in NNK metabolic activation in the 2016 Yuan trial — far smaller than rodent chemoprevention magnitudes — and the absence of cancer incidence endpoints from any human PEITC trial are reminders that mechanistic biomarker effects may not translate into prevention of cancer or extension of healthspan. Definitive trials with hard endpoints have not been undertaken and would require multi-year, large-cohort designs.

Conclusion

PEITC is the most clinically advanced of the dietary isothiocyanates, with multiple completed randomized human trials demonstrating measurable biological effects: reduced metabolic activation of tobacco carcinogens in smokers, enhanced detoxification of environmental volatile organic toxicants in genetically susceptible subgroups, and improved progression-free survival and quality of life when delivered as a functional food in advanced oral cancer. Its mechanisms — induction of detoxification enzymes via cellular antioxidant defense pathways, programmed cancer-cell death from within the mitochondria, suppression of androgen-receptor signaling, and shifts in how genes are switched on or off — are well characterized in laboratory and animal systems and partially confirmed in human pharmacodynamic studies.

The evidence base is concentrated in research groups closely tied to chemoprevention drug development, which is itself a field with structural funding incentives that favor demonstration of activity. The magnitudes of human effect have been modest relative to preclinical promise, and the available trials have measured biomarker and disease-progression outcomes rather than cancer incidence or longevity directly. Authoritative reviewers caution explicitly against concentrated PEITC supplementation because of documented in vitro genotoxicity and concerns about cumulative tissue exposure with chronic intake.

For health- and longevity-oriented adults, the strongest evidence signal sits with regular dietary intake of watercress and other cruciferous vegetables prepared to maximize isothiocyanate yield. Trial-supported evidence for concentrated PEITC is limited to short courses in defined contexts (smokers, advanced oral cancer). PEITC’s signal as a longevity intervention is most clearly visible within a broader cruciferous vegetable pattern rather than as an isolated agent.

Top - Benefits - Risks - Protocol

PEITC for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

Medium 🟩 🟩

Tobacco Carcinogen Detoxification

Improved Outcomes in Advanced Oral Cancer (Adjunctive)

Low 🟩

Anticancer Activity (Preclinical Cancer Chemoprevention)

Reduced Oxidative DNA Damage

Anti-Inflammatory Effects

Speculative 🟨

Anti-Obesity & Metabolic Effects

Antimicrobial & Antiparasitic Activity

Cardiovascular Protection

Neuroprotection

Benefit-Modifying Factors

Potential Risks & Side Effects

Medium 🟥 🟥

Gastrointestinal Side Effects

Low 🟥

Genotoxicity at High Concentrations

Thyroid Disruption (Theoretical)

Speculative 🟨

Renal & Bladder Effects

Drug Interactions via Phase I Inhibition

Embryotoxicity

Cumulative Tissue Burden with Chronic Supplementation

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion